Imaging advance set to speed up quest for cell-based therapies

Cancer treatments that involve transplanting cells into patients could move forward faster thanks to a new imaging system.

Scientists have devised a technique for tracking cells inside the body for up to a week so that doctors can gauge the effectiveness of cell-based therapies.

The system will speed up studies to test if these treatments are safe to use, the researchers say.

With existing technology cells are tagged with chemical agents that emit infra-red light, but these agents degrade quickly, making it challenging to track cells for more than two days.

Now, experts at the University of Edinburgh have developed new chemical agents that emit infra-red light and are stable enough for long-term imaging.

The infra-red light is detected using body scanners without the need for surgery, revealing the exact location of the labelled cells.

Studies with mice found that cells labelled with the agents could be tracked inside the living body for up to seven days.

The chemical label did not affect the function of the tagged cells and was not transferred on to other cells, enabling the team to accurately monitor their fate.

Following the cells for longer periods of time is crucial for showing how they work and proving they are safe.

Researchers say the advance will speed up safety testing of cell-based therapies in both animal studies and human patients. It will also mean that fewer animals are needed for testing.

The research, published in the journal Chemical Science, was carried out at the University’s Medical Research Council Centre for Inflammation Research.

Dr Marc Vendrell, Senior Lecturer in Biomedical Imaging at the University of Edinburgh’s MRC Centre for Inflammation Research, said: “The new agents are a significant advance in

Ranked among the top universities in the world
our ability to follow the fate of cells without surgery. We hope this will ultimately reduce the number of mice used in research and will improve the quality of biomedical imaging studies.”

Professor Richard Mellanby, Head of Veterinary Clinical Research at the University of Edinburgh’s Royal (Dick) School of Veterinary Studies, said: “Long-term tracking of cells in the body has been a major unmet need in biomedical research. We hope these agents will help to speed up the development of cell-based therapies for use in people and animals.”

For more information please contact:
Press & PR Office, 0131 650 9547; 07979446209; press.office@ed.ac.uk